

PATENT Attorney Docket No. 24512-X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

REUSER et al.

Serial No.:

09/886,477

Filing Date:

June 22, 2001

For:

METHODS OF PURIFYING HUMAN ACID ALPHA-GLUCOSIDASE

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents Washington, D.C. 20231

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

merits, whichever event occurs last.

[] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or
-] ii. a check in the amount required by 37 C.F.R. \$ 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.
 - [] Certification report(e) below; and
 - [] a check in the amount as required by § 1.17(p).
- [] d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.

RECEIVED

APR 2 3 2003

TECH CENTER 1600/290

- [] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]
 - [] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

- [] Appropriate certification is attached.
- [X] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- [X] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR § 1.98(d)(1)(2). The earlier application is identified as:

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted, NATH & ASSOCIATES PLLC

Date: #W.Z.

1030 15th Street, N.W., 6th Floor

Washington, D.C. 20005-1503

Tel. (202) 775-8383 Fax. (202) 775-8396

GMN/TLJ (IDS.doc)

By:

/Gary M. Nath

Registration No. 26,965

Todd L. Juneau

Registration No. 40,669

Customer No. 20529

165/



PATENT Attorney Docket No. 24512-X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

RECEIVED

REUSER et al.

APR 2 3 2003

Serial No.:

09/886,477

TECH CENTER 1600/2900

Filing Date:

June 22, 2001

For:

METHODS OF PURIFYING HUMAN ACID ALPHA-GLUCOSIDASE

TRANSMITTAL LETTER

Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

1) Transmittal Letter;

- 2) Second Supplemental Information Disclosure Statement;
- 3) PTO-Form 1449; and
- 4) Twelve (12) Cited References.

The Commissioner is specifically authorized to charge any required fee deficiency under 37 CFR '' 1.16 or 1.17, or credit any overpayment, to Deposit Account No. 14-0112 in connection with this matter.

Respectfully submitted, NATH & ASSOCIATES PLLC

Date:

NATH & ASSOCIATES PLLC

1030 Fifteenth Street, N.W.

Sixth Floor

Washington, D.C. 20005

Tel: (202) 775-8383

Fax: (202) 775-8396

GMN:TLJ:JBG:\2sids.tl.doc

Gary M. Nath

Reg. Nd. 26,965

Todd L. Juneau

Reg. No. 40,669

Customer No. 20529